| Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance L Chang, PH Graham, J Hao, J Ni, J Bucci, PJ Cozzi, JH Kearsley, Y Li Cell death & disease 4 (10), e875-e875, 2013 | 409 | 2013 |
| PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair … L Chang, PH Graham, J Hao, J Ni, J Bucci, PJ Cozzi, JH Kearsley, Y Li Cell death & disease 5 (10), e1437-e1437, 2014 | 329 | 2014 |
| Cancer stem cell in breast cancer therapeutic resistance X Bai, J Ni, J Beretov, P Graham, Y Li Cancer treatment reviews 69, 152-163, 2018 | 300 | 2018 |
| Cancer stem cells: a contentious hypothesis now moving forward ML O’Connor, D Xiang, S Shigdar, J Macdonald, Y Li, T Wang, C Pu, ... Cancer letters 344 (2), 180-187, 2014 | 291 | 2014 |
| Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers N Gao, Y Li, J Li, Z Gao, Z Yang, Y Li, H Liu, T Fan Frontiers in oncology 10, 598817, 2020 | 254 | 2020 |
| Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine D Xiang, S Shigdar, G Qiao, T Wang, AZ Kouzani, SF Zhou, L Kong, Y Li, ... Theranostics 5 (1), 23, 2015 | 252 | 2015 |
| Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell … J Deng, X Bai, X Feng, J Ni, J Beretov, P Graham, Y Li BMC cancer 19, 1-12, 2019 | 224 | 2019 |
| Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway J Ni, P Cozzi, J Hao, J Beretov, L Chang, W Duan, S Shigdar, W Delprado, ... The international journal of biochemistry & cell biology 45 (12), 2736-2748, 2013 | 211 | 2013 |
| RNA aptamers targeting cancer stem cell marker CD133 S Shigdar, L Qiao, SF Zhou, D Xiang, T Wang, Y Li, LY Lim, L Kong, L Li, ... Cancer letters 330 (1), 84-95, 2013 | 206 | 2013 |
| Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance L Chang, PH Graham, J Ni, J Hao, J Bucci, PJ Cozzi, Y Li Critical reviews in oncology/hematology 96 (3), 507-517, 2015 | 198 | 2015 |
| Exosomes and nanoengineering: a match made for precision therapeutics PHL Tran, D Xiang, TTD Tran, W Yin, Y Zhang, L Kong, K Chen, M Sun, ... Advanced Materials 32 (18), 1904040, 2020 | 194 | 2020 |
| Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors D Xiang, C Zheng, SF Zhou, S Qiao, PHL Tran, C Pu, Y Li, L Kong, ... Theranostics 5 (10), 1083, 2015 | 186 | 2015 |
| Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis B Pang, Y Zhu, J Ni, J Thompson, D Malouf, J Bucci, P Graham, Y Li Theranostics 10 (5), 2309, 2020 | 180 | 2020 |
| Cancer stem cell targeted therapy: progress amid controversies T Wang, S Shigdar, MP Gantier, Y Hou, L Wang, Y Li, H Al Shamaileh, ... Oncotarget 6 (42), 44191, 2015 | 180 | 2015 |
| Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? X Bai, J Ni, J Beretov, P Graham, Y Li Cancer letters 497, 100-111, 2021 | 179 | 2021 |
| CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance J Ni, PJ Cozzi, JL Hao, J Beretov, L Chang, W Duan, S Shigdar, ... The Prostate 74 (6), 602-617, 2014 | 172 | 2014 |
| Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression J Hao, H Chen, MC Madigan, PJ Cozzi, J Beretov, W Xiao, WJ Delprado, ... British journal of cancer 103 (7), 1008-1018, 2010 | 166 | 2010 |
| Exosomes and breast cancer drug resistance X Dong, X Bai, J Ni, H Zhang, W Duan, P Graham, Y Li Cell death & disease 11 (11), 987, 2020 | 161 | 2020 |
| MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer PJ Cozzi, J Wang, W Delprado, AC Perkins, BJ Allen, PJ Russell, Y Li Clinical & experimental metastasis 22, 565-573, 2005 | 154 | 2005 |
| Intralesional targeted alpha therapy for metastatic melanoma BJ Allen, C Raja, S Rizvi, Y Li, W Tsui, P Graham, J Thompson, R Reisfeld, ... Cancer biology & therapy 4 (12), 1318-1324, 2005 | 153 | 2005 |
Jie NiUniversity of New South WalesEmail verificata su unsw.edu.au